Dr. Seidman on Ixabepilone in Patients With Aggressive Breast Cancer

Video

Andrew D. Seidman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the label indication for ixabepilone (Ixempra) for the treatment of patients with aggressive breast cancer.

Andrew D. Seidman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the label indication for ixabepilone (Ixempra) for the treatment of patients with aggressive breast cancer.

Ixabepilone represents the importance of having microtubule-binding agents available in the treatment paradigm of breast cancer, Seidman says. Earlier evidence of this was seen with therapies such as vincristine and vinblastine, as well as with the integration of taxanes.

Ixabepilone is approved as a single agent on an every 3-week schedule in patients whose disease is resistant to anthracyclines, taxanes, and capecitabine. In a large phase II study examining ixabepilone, the agent demonstrated a 12% response rate in patients and was associated with a significant median progression-free survival.

<<<

View more from the 33rd Annual Miami Breast Cancer Conference

Related Videos
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
Alexey Danilov, MD, PhD
Hayder Saeed, MD